Durvalumab

Durvalumab
Antigen-binding fragment of durvalumab (pale green) in complex with PD-L1 (pink). PDB: 5X8M​.
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetCD274
Clinical data
Trade namesImfinzi
Other namesMEDI4736, MEDI-4736
AHFS/Drugs.comMonograph
MedlinePlusa617030
License data
Pregnancy
category
Routes of
administration		Intravenous
ATC code
Legal status
Legal status
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6502H10018N1742O2024S42
Molar mass146322.36 g·mol−1

Durvalumab,[11] sold under the brand name Imfinzi, is an anti-cancer medication used for treatment of various types of cancer.[9] It was developed by Medimmune/AstraZeneca.[12] It is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that blocks the interaction of programmed cell death ligand 1 (PD-L1).[9]

Durvalumab is an immune checkpoint inhibitor drug.[13] It was approved in for medical use in the United States in May 2017,[9][12][14][15] and in the European Union in September 2018.[10]

  1. ^ "Durvalumab (Imfinzi) Use During Pregnancy". Drugs.com. 30 August 2019. Archived from the original on 29 August 2021. Retrieved 7 February 2020.
  2. ^ AusPAR: Imfinzi
  3. ^ AusPAR: Durvalumab
  4. ^ "Imfinzi (AstraZeneca Pty Ltd)". Therapeutic Goods Administration (TGA). 5 December 2022. Archived from the original on 18 March 2023. Retrieved 9 April 2023.
  5. ^ "Auspar: Imfinzi". 8 December 2023. Retrieved 18 June 2024.
  6. ^ Australia IMFINZI (AstraZeneca Pty Ltd)
  7. ^ "Regulatory Decision Summary - Imfinzi". Health Canada. 23 October 2014. Archived from the original on 7 June 2022. Retrieved 6 September 2022.
  8. ^ "Cancer therapies". Health Canada. 8 May 2018. Retrieved 13 April 2024.
  9. ^ a b c d Cite error: The named reference Imfinzi FDA label was invoked but never defined (see the help page).
  10. ^ a b "Imfinzi EPAR". European Medicines Agency (EMA). 30 October 2018. Archived from the original on 28 August 2021. Retrieved 30 September 2020.
  11. ^ World Health Organization (2015). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 74". WHO Drug Information. 29 (3). hdl:10665/331070.
  12. ^ a b "Durvalumab (Imfinzi)". U.S. Food and Drug Administration (FDA). Archived from the original on 8 May 2017. Retrieved 6 May 2017.
  13. ^ Syn NL, Teng MW, Mok TS, Soo RA (December 2017). "De-novo and acquired resistance to immune checkpoint targeting". The Lancet. Oncology. 18 (12): e731 – e741. doi:10.1016/s1470-2045(17)30607-1. PMID 29208439.
  14. ^ "FDA approves durvalumab for extensive-stage small cell lung cancer". U.S. Food and Drug Administration (FDA). 27 March 2020. Archived from the original on 4 August 2020. Retrieved 19 July 2024.
  15. ^ Mathieu L, Shah S, Pai-Scherf L, Larkins E, Vallejo J, Li X, et al. (May 2021). "FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer". The Oncologist. 26 (5): 433–438. doi:10.1002/onco.13752. PMC 8100557. PMID 33687763.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.